Drug Shortage Report for MYLAN-NAPROXEN/ESOMEPRAZOLE MR
Report ID | 119316 |
Drug Identification Number | 02458608 |
Brand name | MYLAN-NAPROXEN/ESOMEPRAZOLE MR |
Common or Proper name | NAPROXEN/ESOMEPRAZOLE MR |
Company Name | MYLAN PHARMACEUTICALS ULC |
Market Status | MARKETED |
Active Ingredient(s) | NAPROXEN ESOMEPRAZOLE |
Strength(s) | 375MG 20MG |
Dosage form(s) | TABLET (IMMEDIATE AND DELAYED-RELEASE) |
Route of administration | ORAL ORAL |
Packaging size | 60BT |
ATC code | M01AE |
ATC description | ANTIINFLAMMATORY/ANTIRHEUMATIC PROD.,NON-STEROIDS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | 2020-07-15 |
Actual start date | 2020-07-11 |
Estimated end date | 2020-09-29 |
Actual end date | 2020-09-30 |
Shortage status | Resolved |
Updated date | 2020-10-01 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 85 ADVANCE ROAD ETOBICOKE, ONTARIO CANADA M8Z 2S6 |
Company contact information | Mylan Pharmaceuticals ULC, 85 Advance Road, Etobicoke, ON, M8Z 2S6 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v21 | 2020-10-01 | English | Compare |